First Header Logo Second Header Logo

Connection

Peter Clark to Aged, 80 and over

Back to Details
This is a "connection" page, showing publications Peter Clark has written about Aged, 80 and over.
Peter Clark
Connection Strength
1.034
Aged, 80 and over
  1. Glaser ZA, Love HD, Guo S, Gellert L, Chang SS, Herrell SD, Barocas DA, Penson DF, Cookson MS, Clark PE. TPX2 as a prognostic indicator and potential therapeutic target in clear cell renal cell carcinoma. Urol Oncol. 2017 05; 35(5):286-293.
    View in: PubMed
    Score: 0.085
  2. Kaffenberger SD, Morgan TM, Stratton KL, Boachie AM, Barocas DA, Chang SS, Cookson MS, Herrell SD, Smith JA, Clark PE. ABO blood group is a predictor of survival in patients undergoing surgery for renal cell carcinoma. BJU Int. 2012 Dec; 110(11 Pt B):E641-6.
    View in: PubMed
    Score: 0.063
  3. Fowke JH, Phillips S, Koyama T, Byerly S, Concepcion R, Motley SS, Clark PE. Association between physical activity, lower urinary tract symptoms (LUTS) and prostate volume. BJU Int. 2013 Jan; 111(1):122-8.
    View in: PubMed
    Score: 0.062
  4. Boudreaux KJ, Chang SS, Lowrance WT, Rumohr JA, Barocas DA, Cookson MS, Smith JA, Clark PE. Comparison of American Joint Committee on Cancer pathologic stage T3a versus T3b urothelial carcinoma: analysis of patient outcomes. Cancer. 2009 Feb 15; 115(4):770-5.
    View in: PubMed
    Score: 0.049
  5. Coons BJ, Stec AA, Stratton KL, Chang SS, Cookson MS, Duke Herrell S, Smith JA, Clark PE. Prognostic factors in T3b renal cell carcinoma. World J Urol. 2009 Feb; 27(1):75-9.
    View in: PubMed
    Score: 0.048
  6. Stec AA, Coons BJ, Chang SS, Cookson MS, Herrell SD, Smith JA, Clark PE. Waiting time from initial urological consultation to nephrectomy for renal cell carcinoma--does it affect survival? J Urol. 2008 Jun; 179(6):2152-7.
    View in: PubMed
    Score: 0.046
  7. Zagoria RJ, Traver MA, Werle DM, Perini M, Hayasaka S, Clark PE. Oncologic efficacy of CT-guided percutaneous radiofrequency ablation of renal cell carcinomas. AJR Am J Roentgenol. 2007 Aug; 189(2):429-36.
    View in: PubMed
    Score: 0.044
  8. Clark PE, Woodruff RD, Zagoria RJ, Hall MC. Microwave ablation of renal parenchymal tumors before nephrectomy: phase I study. AJR Am J Roentgenol. 2007 May; 188(5):1212-4.
    View in: PubMed
    Score: 0.043
  9. Clark PE, Hall MC, Borden LS, Miller AA, Hu JJ, Lee WR, Stindt D, D'Agostino R, Lovato J, Harmon M, Torti FM. Phase I-II prospective dose-escalating trial of lycopene in patients with biochemical relapse of prostate cancer after definitive local therapy. Urology. 2006 Jun; 67(6):1257-61.
    View in: PubMed
    Score: 0.041
  10. Clark PE, Veys JA, Eskridge MR, Woodruff RD, Hall MC. Prognostic significance of clinicopathologic and deoxyribonucleic acid flow cytometric variables in non-metastatic renal cell carcinoma in the modern era. Urol Oncol. 2005 Sep-Oct; 23(5):328-32.
    View in: PubMed
    Score: 0.039
  11. Clark PE, Stein JP, Groshen SG, Cai J, Miranda G, Lieskovsky G, Skinner DG. Radical cystectomy in the elderly: Comparison of survival between younger and older patients. Cancer. 2005 Feb 01; 103(3):546-52.
    View in: PubMed
    Score: 0.037
  12. Clark PE, Stein JP, Groshen SG, Miranda G, Cai J, Lieskovsky G, Skinner DG. The management of urethral transitional cell carcinoma after radical cystectomy for invasive bladder cancer. J Urol. 2004 Oct; 172(4 Pt 1):1342-7.
    View in: PubMed
    Score: 0.036
  13. Clark PE, Hall MC, Miller A, Ridenhour KP, Stindt D, Lovato JF, Patton SE, Brinkley W, Das S, Torti FM. Phase II trial of combination interferon-alpha and thalidomide as first-line therapy in metastatic renal cell carcinoma. Urology. 2004 Jun; 63(6):1061-5.
    View in: PubMed
    Score: 0.035
  14. Clark PE, Schover LR, Uzzo RG, Hafez KS, Rybicki LA, Novick AC. Quality of life and psychological adaptation after surgical treatment for localized renal cell carcinoma: impact of the amount of remaining renal tissue. Urology. 2001 Feb; 57(2):252-6.
    View in: PubMed
    Score: 0.028
  15. Burgess EF, Livasy C, Trufan S, Hartman A, Guerreri R, Naso C, Clark PE, Grigg C, Symanowski J, Raghavan D. High aurora kinase expression identifies patients with muscle-invasive bladder cancer who have poor survival after neoadjuvant chemotherapy. Urol Oncol. 2019 12; 37(12):900-906.
    View in: PubMed
    Score: 0.026
  16. Clark PE, Streem SB, Geisinger MA. 13-year experience with percutaneous management of upper tract transitional cell carcinoma. J Urol. 1999 Mar; 161(3):772-5; discussion 775-6.
    View in: PubMed
    Score: 0.025
  17. Goldstein J, Borowsky AD, Goyal R, Roland JT, Arnold SA, Gellert LL, Clark PE, Hameed O, Giannico GA. MAGI-2 in prostate cancer: an immunohistochemical study. Hum Pathol. 2016 06; 52:83-91.
    View in: PubMed
    Score: 0.020
  18. Arnold SA, Loomans HA, Ketova T, Andl CD, Clark PE, Zijlstra A. Urinary oncofetal ED-A fibronectin correlates with poor prognosis in patients with bladder cancer. Clin Exp Metastasis. 2016 Jan; 33(1):29-44.
    View in: PubMed
    Score: 0.019
  19. Corcoran AT, Kaffenberger SD, Clark PE, Walton J, Handorf E, Piotrowski Z, Tomaszewski JJ, Ginzburg S, Mehrazin R, Plimack E, Chen DY, Smaldone MC, Uzzo RG, Morgan TM, Kutikov A. Hypoalbuminaemia is associated with mortality in patients undergoing cytoreductive nephrectomy. BJU Int. 2015 Sep; 116(3):351-7.
    View in: PubMed
    Score: 0.018
  20. Tang DH, Clark PE, Giannico G, Hameed O, Chang SS, Gellert LL. Lack of P16ink4a over expression in penile squamous cell carcinoma is associated with recurrence after lymph node dissection. J Urol. 2015 Feb; 193(2):519-25.
    View in: PubMed
    Score: 0.018
  21. Morgan TM, Barocas DA, Keegan KA, Cookson MS, Chang SS, Ni S, Clark PE, Smith JA, Penson DF. Volume outcomes of cystectomy--is it the surgeon or the setting? J Urol. 2012 Dec; 188(6):2139-44.
    View in: PubMed
    Score: 0.016
  22. Morgan TM, Barocas DA, Penson DF, Chang SS, Ni S, Clark PE, Smith JA, Cookson MS. Lymph node yield at radical cystectomy predicts mortality in node-negative and not node-positive patients. Urology. 2012 Sep; 80(3):632-40.
    View in: PubMed
    Score: 0.016
  23. Patel SG, Penson DF, Pabla B, Clark PE, Cookson MS, Chang SS, Herrell SD, Smith JA, Barocas DA. National trends in the use of partial nephrectomy: a rising tide that has not lifted all boats. J Urol. 2012 Mar; 187(3):816-21.
    View in: PubMed
    Score: 0.015
  24. Broughton GJ, Clark PE, Barocas DA, Cookson MS, Smith JA, Herrell SD, Chang SS. Tumour size, tumour complexity, and surgical approach are associated with nephrectomy type in small renal cortical tumours treated electively. BJU Int. 2012 Jun; 109(11):1607-13.
    View in: PubMed
    Score: 0.015
  25. Morgan TM, Barocas DA, Chang SS, Phillips SE, Salem S, Clark PE, Penson DF, Smith JA, Cookson MS. The relationship between perioperative blood transfusion and overall mortality in patients undergoing radical cystectomy for bladder cancer. Urol Oncol. 2013 Aug; 31(6):871-7.
    View in: PubMed
    Score: 0.015
  26. Morgan TM, Keegan KA, Barocas DA, Ruhotina N, Phillips SE, Chang SS, Penson DF, Clark PE, Smith JA, Cookson MS. Predicting the probability of 90-day survival of elderly patients with bladder cancer treated with radical cystectomy. J Urol. 2011 Sep; 186(3):829-34.
    View in: PubMed
    Score: 0.015
  27. Stec AA, Stratton KL, Kaufman MR, Chang SS, Milam DF, Herrell SD, Dmochowski RR, Smith JA, Clark PE, Cookson MS. Open renal biopsy: comorbidities and complications in a contemporary series. BJU Int. 2010 Jul; 106(1):102-6.
    View in: PubMed
    Score: 0.013
  28. Barocas DA, Patel SG, Chang SS, Clark PE, Smith JA, Cookson MS. Outcomes of patients undergoing radical cystoprostatectomy for bladder cancer with prostatic involvement on final pathology. BJU Int. 2009 Oct; 104(8):1091-7.
    View in: PubMed
    Score: 0.012
  29. Patel SG, Cookson MS, Barocas DA, Clark PE, Smith JA, Chang SS. Risk factors for urothelial carcinoma of the prostate in patients undergoing radical cystoprostatectomy for bladder cancer. BJU Int. 2009 Oct; 104(7):934-7.
    View in: PubMed
    Score: 0.012
  30. Boudreaux KJ, Clark PE, Lowrance WT, Rumohr JA, Barocas DA, Cookson MS, Smith JA, Chang SS. Comparison of american joint committee on cancer pathological stage T2a versus T2b urothelial carcinoma: analysis of patient outcomes in organ confined bladder cancer. J Urol. 2009 Feb; 181(2):540-5; discussion 546.
    View in: PubMed
    Score: 0.012
  31. Chan RC, Barocas DA, Chang SS, Herrell SD, Clark PE, Baumgartner R, Smith JA, Cookson MS. Effect of a large prostate gland on open and robotically assisted laparoscopic radical prostatectomy. BJU Int. 2008 May; 101(9):1140-4.
    View in: PubMed
    Score: 0.012
  32. Lowrance WT, Rumohr JA, Chang SS, Clark PE, Smith JA, Cookson MS. Contemporary open radical cystectomy: analysis of perioperative outcomes. J Urol. 2008 Apr; 179(4):1313-8; discussion 1318.
    View in: PubMed
    Score: 0.011
  33. Smith JA, Chan RC, Chang SS, Herrell SD, Clark PE, Baumgartner R, Cookson MS. A comparison of the incidence and location of positive surgical margins in robotic assisted laparoscopic radical prostatectomy and open retropubic radical prostatectomy. J Urol. 2007 Dec; 178(6):2385-9; discussion 2389-90.
    View in: PubMed
    Score: 0.011
  34. Yacoub J, Richardson C, Farmer M, Lee WR, Clark PE, Hurt G, Levine EA. Male breast cancer during treatment with leuprolide for prostate cancer. Clin Adv Hematol Oncol. 2007 Jul; 5(7):555-6; discussion 556-7.
    View in: PubMed
    Score: 0.011
  35. Papagikos MA, Rossi PJ, Urbanic JJ, deGuzman AF, McCullough DL, Clark PE, Lee WR. A simple model predicts freedom from biochemical recurrence after low-dose rate prostate brachytherapy alone. Am J Clin Oncol. 2007 Apr; 30(2):199-204.
    View in: PubMed
    Score: 0.011
  36. Borden LS, Clark PE, Lovato J, Hall MC, Stindt D, Harmon M, M Mohler R, Torti FM. Vinorelbine, doxorubicin, and prednisone in androgen-independent prostate cancer. Cancer. 2006 Sep 1; 107(5):1093-100.
    View in: PubMed
    Score: 0.010
  37. Rossi PJ, Clark PE, Papagikos MA, McCullough DL, Lee WR. Percentage of positive biopsies associated with freedom from biochemical recurrence after low-dose-rate prostate brachytherapy alone for clinically localized prostate cancer. Urology. 2006 Feb; 67(2):349-53.
    View in: PubMed
    Score: 0.010
  38. Papagikos MA, Deguzman AF, Rossi PJ, McCullough DL, Clark PE, Lee WR. Dosimetric quantifiers for low-dose-rate prostate brachytherapy: is V(100) superior to D(90)? Brachytherapy. 2005; 4(4):252-8.
    View in: PubMed
    Score: 0.009
  39. Kubinski DJ, Clark PE, Assimos DG, Hall MC. Utility of frozen section analysis of resection margins during partial nephrectomy. Urology. 2004 Jul; 64(1):31-4.
    View in: PubMed
    Score: 0.009
  40. Quek ML, Stein JP, Clark PE, Daneshmand S, Miranda G, Cai J, Groshen S, Cote RJ, Lieskovsky G, Quinn DI, Skinner DG. Microscopic and gross extravesical extension in pathological staging of bladder cancer. J Urol. 2004 Feb; 171(2 Pt 1):640-5.
    View in: PubMed
    Score: 0.009
  41. Quek ML, Stein JP, Clark PE, Daneshmand S, Miranda G, Cai J, Groshen S, Lieskovsky G, Quinn DI, Raghavan D, Skinner DG. Natural history of surgically treated bladder carcinoma with extravesical tumor extension. Cancer. 2003 Sep 01; 98(5):955-61.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.